肿瘤坏死因子-α抑制剂与血流感染:全国性病例对照研究
OBJECTIVES: Severe infection risk associated with tumour necrosis factor-α inhibitors (TNFis) remains a concern. We aimed to assess the association between TNFi and bloodstream infections (BSIs) in a population-based setting.…
要点
- TNFi使用者血流感染风险显著升高,阿达木单抗和英夫利西单抗风险更高。
- 常见病原体如大肠埃希菌、金黄色葡萄球菌、肺炎链球菌和屎肠球菌感染风险均升高。
- 炎症性肠病患者风险最高,联用糖皮质激素进一步增加风险。
核心结论
- TNFi使用与血流感染风险升高相关,且见于最常见病原体。
- 风险因TNFi类型和基础疾病而异,炎症性肠病患者风险最高。
研究设计与样本
- TNFi暴露定义为血流感染日期前6个月内使用。
- 采用条件logistic回归估计调整比值比(aOR)及95%置信区间(CI)。
主要发现
- TNFi使用者血流感染风险较非使用者升高(aOR 1.41;95%CI 1.30-1.52)。
- 阿达木单抗(aOR 1.51;95%CI 1.33-1.72)和英夫利西单抗(aOR 2.01;95%CI 1.76-2.29)使用者风险升高。
- 大肠埃希菌(aOR 1.33;95%CI 1.16-1.53)、金黄色葡萄球菌(aOR 1.69;95%CI 1.40-2.06)、肺炎链球菌(aOR 1.46;95%CI 1.05-2.04)和屎肠球菌(aOR 1.62;95%CI 1.04-2.53)血流感染风险升高。
- 炎症性肠病患者风险最高(aOR 2.27;95%CI 1.93-2.66),其次为类风湿关节炎患者。
- 与TNFi单药治疗相比,联用糖皮质激素增加风险(aOR 2.63;95%CI 2.06-3.36)。
临床怎么用
- 对TNFi使用者应个体化评估感染风险,尤其炎症性肠病患者。
- 关注英夫利西单抗和阿达木单抗使用者的血流感染风险。
- 尽量避免TNFi与糖皮质激素联用以降低感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Severe infection risk associated with tumour necrosis factor-α inhibitors (TNFis) remains a concern. We aimed to assess the association between TNFi and bloodstream infections (BSIs) in a population-based setting. METHODS: Nationwide, registry-based case-control study including all adults from 2010 to 2024 with a first-time microbiologically confirmed BSI (cases) compared with age and sex-matched controls from the general population. Users were defined as individuals with TNFi exposure within 6 months prior to the date of BSIs. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were estimated using conditional logistic regression. We further assessed risk variation by type of TNFi, pathogen, and underlying disease. RESULTS: We included 174,137 cases and 1 741 294 controls. Users had significantly increased odds of BSIs compared with nonusers (aOR, 1.41; 95% CI, 1.30-1.52), driven by increased odds among users of adalimumab and infliximab (aOR, 1.51; 95% CI, 1.33-1.72, and aOR, 2.01; 95% CI, 1.76-2.29). The use of certolizumab pegol and etanercept was associated with lower odds of BSIs, and golimumab with higher odds compared with nonuse, although not statistically significant. Species-specific analyses showed increased odds of BSIs with Escherichia coli (aOR, 1.33; 95% CI, 1.16-1.53), Staphylococcus aureus (aOR, 1.69; 95% CI, 1.40-2.06), Streptococcus pneumoniae (aOR, 1.46; 95% CI, 1.05-2.04), and Enterococcus faecium (aOR, 1.62; 95% CI, 1.04-2.53). Highest odds were observed in individuals with inflammatory bowel disease (aOR, 2.27; 95% CI, 1.93-2.66), followed by individuals with rheumatoid arthritis. Compared with TNFi monotherapy, concomitant glucocorticoids increased the odds (aOR, 2.63; 95% CI, 2.06-3.36). CONCLUSIONS: TNFi use is associated with increased odds of BSIs and was observed across the most frequent species. Odds varied by TNFi type and underlying disease, with the highest odds among patients with inflammatory bowel disease, emphasizing the need for individualized infection risk assessment.
引用
- Leding C, Meddis A, Holler JG, et al. Tumour necrosis factor-α inhibitors, immune-mediated inflammatory diseases, and bloodstream infections: results from a nationwide case-control study. Clin Microbiol Infect. 2026. PMID: 41690515. doi:10.1016/j.cmi.2026.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。